Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Saved in:
| Title: | Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. |
|---|---|
| Authors: | Paller AS; Northwestern University Feinberg Medical School, Chicago, Illinois. Electronic address: apaller@northwestern.edu., Hong Y; Celgene Corporation, Summit, New Jersey., Becker EM; University of Texas Health Science Center-San Antonio, San Antonio, Texas., de Lucas R; Hospital Universitario La Paz, Madrid, Spain., Paris M; Celgene Corporation, Summit, New Jersey., Zhang W; Celgene Corporation, Summit, New Jersey., Zhang Z; Celgene Corporation, Summit, New Jersey., Barcellona C; Celgene Corporation, Summit, New Jersey., Maes P; Celgene Corporation, Summit, New Jersey., Fiorillo L; Pediatric Department, University of Alberta, Edmonton, Canada. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Feb; Vol. 82 (2), pp. 389-397. Date of Electronic Publication: 2019 Aug 10. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1097-6787 |
|---|---|
| DOI: | 10.1016/j.jaad.2019.08.019 |
